Fresenius Kabi doesn't have relative market power for certain feeds vis-à-Vis Galexis, Swiss watchdog says
MLex Summary: Fresenius Kabi doesn’t have ‘’relative market power’’ vis-à-vis Galexis when it comes to oral and tube feeds, the Swiss competition authority said today. This finding ends the watchdog’s first...To view the full article, register now.
Already a subscriber? Click here to view full article